Table 1.
The demographic details of the patients
| Patient | Age/ gender |
Disease duration (years) |
Motor UPDRS OFF/ON |
Hoehn Yahr Score |
L-dopa equivalent doses (mg/day) |
Side of micro- electrode tract of nuclei | No. of neuron analyzed | ||
|---|---|---|---|---|---|---|---|---|---|
| 4–5 Hz band oscillatory neuron(%) | βFB oscillatory neuron (%) | non-oscillatory neuron (%) | |||||||
| 1 | 46/M | 2 | 63.5/35.5 | 2.5 | 600 | B-STN | 2(28.6) | 2(28.6) | 3(42.9) |
| 2 | 57/F | 4 | 40/16.5 | 2.5 | 600 | B-STN | 6(85.7) | 1(14.3) | 0(0) |
| 3 | 67/M | 7 | 62.5/43 | 4 | 775 | B-STN | 6(54.5) | 3(27.3) | 2(18.2) |
| 4 | 56/M | 8 | 20/12 | 1.5 | 750 | L-STN | 3(42.9) | 2(28.6) | 2(28.6) |
| 5 | 62/F | 10 | 41.5/21 | 3 | 150 | R-STN | 4(80) | 0(0) | 1(20) |
| 6 | 71/F | 10 | 40/19 | 3 | 675 | L-STN | 2(33.3) | 2(33.3) | 2(33.3) |
| 7 | 56/M | 5 | 45/25.5 | 2.5 | 250 | L-STN | 3(37.5) | 1(12.5) | 4(50) |
| 8 | 64/F | 12 | 57.5/40 | 3 | 375 | R-STN | 4(50) | 0(0) | 4(50) |
| 9 | 67/M | 4 | 30/18.5 | 2.5 | 400 | L(STN) | 0(0) | 2(50) | 2(50) |
| 10 | 66/F | 7 | 61.5/31 | 3 | 600 | B-STN | 0(0) | 9(90) | 1(10) |
| 11 | 68/M | 4 | 52/26.5 | 2.5 | 675 | B-STN | 0(0) | 0(0) | 3(100) |
| 12 | 61/F | 5 | 44.5/24.5 | 2 | 300 | L-GPi | 1(14.3) | 2(28.6) | 4(57.1) |
| 13 | 59/F | 6 | 42.5/25.5 | 2.5 | 600 | L-GPi | 4(44.4) | 2(22.2) | 3(33.3) |
| 14 | 57/M | 6 | 56.5/32 | 3 | 600 | R-GPi | 8(66.7) | 2(16.7) | 2(16.7) |
| 15 | 62/F | 5 | 60/37.5 | 2.5 | 150 | R-GPi | 2(33.3) | 2(33.3) | 2(33.3) |
| 16 | 51/F | 7 | 52.5/26.5 | 2.5 | 400 | L-GPi | 3(30) | 2(20) | 5(50) |
| 17 | 48/M | 5 | 32.5/18 | 2.5 | 300 | R-GPi | 4(66.7) | 1(16.7) | 1(16.7) |
| 18 | 58/M | 10 | 59.5/33.5 | 4 | 600 | L-GPi | 1(20) | 2(40) | 2(40) |
| 19 | 61/M | 8 | 42/23.5 | 2.5 | 1200 | L-GPi | 0(0) | 1(50) | 1(50) |
| 20 | 56/F | 6 | 49/28 | 3 | 1800 | R-GPi | 0(0) | 3(60) | 2(40) |
| 21 | 61/M | 1 | 35/17.5 | 1.5 | 300 | L-Vop/Vim | 4(40)/3(30) | 1(10)/1(10) | 1(10)/0(0) |
| 22 | 68/M | 5 | 30/15.5 | 1.5 | 200 | L-Vop/Vim | 5(50)/0(0) | 0(0)/0(0) | 3(30)/2(20) |
| 23 | 67/F | 15 | 53/33 | 3 | 800 | L-Vop/Vim | 3(50)/3(50) | 0(0)/0(0) | 0(0)/0(0) |
| 24 | 49/M | 6 | 55/32 | 2.5 | 600 | R-Vop/Vim | 4(44.4)/4(44.4) | 0(0)/0(0) | 1(11.1)/0(0) |
| 25 | 70/M | 3 | 33/20 | 1.5 | 400 | R-Vop/Vim | 6(54.5)/1(9.1) | 1(9.1)/1(9.1) | 1(9.1)/1(9.1) |
| 26 | 64/F | 2 | 39.5/27.5 | 2.5 | 600 | R-Vop/Vim | 0(0)/2(100) | 0(0)/0(0) | 0(0)/0(0) |
| 27 | 56/F | 9 | 46.5/28.5 | 4 | 400 | L-Vop/Vim | 5(50)/3(30) | 0(0)/1(10) | 0(0)/1(10) |
| 28 | 49/F | 2 | 37.5/20.5 | 1.5 | 600 | L-Vop/Vim | 2(18.2)/5(45.5) | 2(18.2)/1(9.1) | 1(9.1)/0(0) |
| 29 | 61/M | 3 | 36.5/24 | 2.5 | 600 | R-Vop/Vim | 0(0)/0(0) | 0(0)/0(0) | 4(80)/1(20) |
Patients 1–11 belong to STN group, patients 12–20 belong to GPi group, patients 21–29 belong to Vop/Vim group; M, male; F, female; UPDRS, United Parkinson’s Disease Rating Scale; L-dopa equivalent daily doses (mg), calculated as sum of the dose of regular levodopa-benserazide or levodopa-carbidopa; B, Bilateral; L, Left; R, Right; No: number; βFB: β frequency band oscillatory neurons; STN: the subthalamic nucleus; GPi: the globus pallidus internus; Vop: the ventral oral posterior nucleus of thalamus; Vim: the ventral intermediate of thalamus